Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: A long-term, retrospective analysis

European Journal of Neurology

Volumn 16, Issue 12, 2009, Pages 1305-1311

  Nissinen, H ^a   Kuoppamaki M ^a,b   Leinonen, M ^c   Schapira, A H ^d  

^a ORION CORPORATION   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c University of Turku ^*  (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Entacapone; Levodopa; Parkinson's disease; Wearing off

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; SELEGILINE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FALLING; FATIGUE; FEMALE; HALLUCINATION; HUMAN; HYPERHIDROSIS; HYPERKINESIA; HYPOKINESIA; INSOMNIA; LIVER TOXICITY; LONG TERM CARE; MALE; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PARKINSONISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; URINALYSIS; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATECHOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 70349259923     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02726.x     Document Type: Article

References (23)

1. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007 64 : 1083 1088.
2. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994 44 : 913 919.
3. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996 19 : 283 296.
4. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994 44 : 77 80.
5. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004 62 : S56 S63.
6. Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006 21 : 332 336.
7. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997 42 : 747 755.
8. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998 51 : 1309 1314.
9. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002 105 : 245 255.
10. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003 74 : 1071 1079.
11. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003 10 : 137 146.
12. Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J Neural Transm 2008 115 : 843 849.
13. Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J Neurol 2008 15 : 268 273.
14. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford, England : Clarendon Press, 1995.
15. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006 59 : 559 562.
16. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004 61 : 561 566.
17. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006 5 : 845 854.
18. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 351 : 2498 2508.
19. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomised controlled trial. JAMA 2000 284 : 1931 1938.
20. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005 20 : 726 733.
21. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO [Lasting effect in Adjunct therapy with Rasagiline Given Once daily] study): a randomised, double-blind, parallel-group trial. Lancet 2005 365 : 947 954.
22. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008 23 : 1428 1434.
23. Schapira AH. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 2008 23 : S515 S520.